Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.
作者信息
Niu Man Man, Cao Yue, Li Rui Xue, Fan Guo Zhen, Hu Peng
机构信息
Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
出版信息
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
Abstract
摘要
相似文献
1
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.接受托珠单抗治疗的2019冠状病毒病（COVID-19）患者的结局异质性
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
2
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
3
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?托珠单抗降低重症 COVID-19 患者死亡率：我们应如何对其进行分级？
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
4
Tocilizumab; A Potential Remedy Against The Ever-Evolving Threat Of Coronavirus-2 (SARS-Cov-2).托珠单抗：应对不断演变的新型冠状病毒2（SARS-CoV-2）威胁的一种潜在疗法。
J Pak Med Assoc. 2023 Aug;73(8):1776-1777. doi: 10.47391/JPMA.8551.
5
Impact of Tocilizumab on the Mortality of Patients With Coronavirus Disease 2019.托珠单抗对2019冠状病毒病患者死亡率的影响。
Clin Infect Dis. 2021 Jun 15;72(12):e1156-e1157. doi: 10.1093/cid/ciaa1738.
6
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM.回复：在炎症标志物升高的住院COVID-19患者中早期使用托珠单抗；COVIDSTORM研究。
Clin Microbiol Infect. 2022 Nov;28(11):1519. doi: 10.1016/j.cmi.2022.06.013. Epub 2022 Jun 20.
7
Rational use of tocilizumab in COVID-19.
Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31.
8
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.托珠单抗使用时机对住院的2019冠状病毒病感染患者的影响
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
9
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.接受糖皮质激素联合或不联合托珠单抗治疗COVID-19相关过度炎症的患者对SARS-CoV-2的抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1362-1363. doi: 10.1136/annrheumdis-2021-220040. Epub 2021 May 6.
10
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
引用本文的文献
1
Characteristics and Risk Factors for Mortality in Critically Ill Patients with COVID-19 Receiving Invasive Mechanical Ventilation: The Experience of a Private Network in Sao Paulo, Brazil.接受有创机械通气的COVID-19危重症患者的死亡特征及危险因素：巴西圣保罗一个私立网络的经验
J Crit Care Med (Targu Mures). 2022 Aug 12;8(3):165-175. doi: 10.2478/jccm-2022-0015. eCollection 2022 Jul.
Zotero 插件